In a filing, Editas Medicine Inc revealed its SVP, Chief Financial Officer Parison Amy unloaded Company’s shares for reported $769.0 on Jun 03 ’25. In the deal valued at $1.72 per share,446 shares were sold. As a result of this transaction, Parison Amy now holds 17,506 shares worth roughly $55143.9.
Then, Burkly Linda sold 726 shares, generating $1,252 in total proceeds. Upon selling the shares at $1.72, the EVP, CHIEF SCIENTIFIC OFFICER now owns 69,519 shares.
Before that, O’Neill Gilmore Neil sold 15,192 shares. Editas Medicine Inc shares valued at $26,196 were divested by the CEO at a price of $1.72 per share. As a result of the transaction, O’Neill Gilmore Neil now holds 280,282 shares, worth roughly $0.88 million.
H.C. Wainwright initiated its Editas Medicine Inc [EDIT] rating to a Buy in a research note published on April 28, 2025; the price target was $3. A number of analysts have revised their coverage, including JP Morgan’s analysts, who decreased its forecast for the stock in mid December from “a Neutral” to “an Underweight”. Truist also remained covering EDIT and has decreased its forecast on December 13, 2024 with a “Hold” recommendation from previously “Buy” rating. Stifel revised its rating on December 13, 2024. It rated EDIT as “a Hold” which previously was an “a Buy”.
Price Performance Review of EDIT
On Monday, Editas Medicine Inc [NASDAQ:EDIT] saw its stock jump 14.13% to $3.15. Over the last five days, the stock has gained 10.53%. Editas Medicine Inc shares have fallen nearly -44.93% since the year began. Nevertheless, the stocks have risen 148.03% over the past one year.
How much short interest is there in Editas Medicine Inc?
A steep rise in short interest was recorded in Editas Medicine Inc stocks on 2025-06-13, dropping by -0.67 million shares to a total of 8.43 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 9.09 million shares. There was a decline of -7.9%, which implies that there is a negative sentiment for the stock.
